AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02586415 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular Thrombectomy
Description: Patients will be treated with thrombectomy devices (stent-retrievers) and/or suction thrombectomy systems currently cleared by the FDA for thrombus removal in patients experiencing an acute stroke following the published instructions for use for these devices. These devices will be used between 6 and 16 hours following symptom onset in DEFUSE 3 based on an FDA IDE. The devices which will be used are the Trevo Retriever, the Solitaire Revascularization Device and the Penumbra system thrombectomy system.
Study NCT02586415 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trevo Retriever
Description: Trevo Retriever is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
Study NCT02586415 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Solitaire™ FR Revascularization Device
Description: Solitaire™ FR Revascularization Device is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
Study NCT02586415 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Penumbra thrombectomy system
Description: Penumbra thrombectomy system is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure. The Penumbra System includes:~• Penumbra Aspiration Pump (1115V) Penumbra System 054 Penumbra System MAX Penumbra System 110 Aspiration Tubing Penumbra System \[026, 032, 041\] Penumbra System Separator Flex \[026, 032, 041, 054\] Penumbra Pump MAX Penumbra System Reperfusion Catheter ACE64 \& ACE68
Study NCT02586415 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Covidien MindFrame Capture Revascularization Device
Description: Covidien MindFrame Capture Revascularization Device is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
Study NCT00443209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telcagepant 300 mg soft gel capsules
Description: One capsule taken orally at onset of migraine
Study NCT00443209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telcagepant 280 mg tablets
Description: One tablet taken orally at onset of migraine
Study NCT00443209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rizatriptan 10 mg tablets
Description: One tablet taken orally at onset of migraine
Study NCT00443209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to telcagepant capsules
Description: One capsule taken orally at onset of migraine
Study NCT00443209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to telcagepant tablets
Description: One tablet taken orally at onset of migraine
Study NCT00443209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to rizatriptan tablets
Description: One tablet taken orally at onset of migraine
Study NCT01206699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticoid (altim® 1.5 ml)
Description: Active arm : anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with corticoid (altim® 1.5 ml)
Study NCT01206699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: physiological solution (1.5 ml)
Description: Control arm: anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with physiological solution (1.5 ml)
Study NCT04563299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: All eyes (n=40) will receive anti-VEGF injections for the treatment of AMD, DME and macular edema secondary to RVO. Twenty eyes (one eye per patient) will be randomized to receive Dextenza. The contra-lateral eye (Control) will receive a sham dilation.
Study NCT04563299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate
Description: All eyes (n=40) will receive anti-VEGF injections for the treatment of AMD, DME and macular edema secondary to RVO. Twenty eyes (one eye per patient) will be randomized to receive Dextenza. The contra-lateral eye (Control) will receive topical corticosteroids (prednisolone acetate 1%) QID tapered over 4 weeks (QID/ 1 week, TID/ 1 week, BID/1 week, QD/ 1 week).
Study NCT04457817 — intervention group
Intervention type: DEVICE
Intervention: CRI
Description: Monitoring via CRI
Study NCT02342145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab,
Description: Basiliximab was used 10mg each time on 0d(after transplantation) and +4 d .
Study NCT02342145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine A
Description: Specifically cyclosporine A was used by intravenous drip infusion on 2mg/kg dosage from -1d and change to 5mg/kg twice oral when gastrointestinal function recovers. The blood concentrations of cyclosporine A was maintained 150-250ng/ml.
Study NCT02342145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine A
Description: Specifically cyclosporine A was used by intravenous drip infusion on 2mg/kg dosage from -1d and change to 5mg/kg twice oral when gastrointestinal function recovers. The blood concentrations of cyclosporine A was maintained 150-250ng/ml.
Study NCT02342145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate was used 15mg/m2 on +1d and 10mg/m2 on +3,+6,+11d by intravenous for prevention of graft-versus-host-disease.
Study NCT02342145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate was used 15mg/m2 on +1d and 10mg/m2 on +3,+6,+11d by intravenous for prevention of graft-versus-host-disease.
Study NCT02342145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil was used 0.25g qd from 0d to 3 months for prevention of graft-versus-host-disease.
Study NCT02342145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil was used 0.25g qd from 0d to 3 months for prevention of graft-versus-host-disease.
Study NCT03235362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR1705
Description: Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days in each period.
Study NCT02598778 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Deionized water
Description: 30 second oral rinse of 10mL of solution
Study NCT02066597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thrombectomy
Description: Within 96 hours of enrolment, patients will be treated with a single session of PMT using an AngioJet catheter without adjuvant thrombolysis . Venous access will be obtained at the popliteal vein in all patients with a 5-F sheath through which all subsequent venography procedures will be performed. The AngioJet catheter will then be passed over the guide wire and moved from proximal to distal to remove thrombus. Completion venography will be performed through the sheath in all patients. After the completion of the procedure patients are expected to remain in hospital for no more than six hours (1 hour in post-anaesthesia care unit followed by transfer to the surgical daycare unit from where they will be discharged).
Study NCT00696995 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Start dose and frequency as well as dose alterations to be determined by the physician according to normal clinical evaluation
Study NCT03421275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: anesthetic used as analgetic in subanesthetic doses given intranasally
Study NCT03421275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Citrate
Description: intravenous fentanyl given intranasally
Study NCT03421275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Nasal
Description: intravenous saline given intranasally as placebo
Study NCT02958410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD30-CAR-transduced T cells
Description: The first 3 enrolled patients will receive autologous-derived CD30-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
Study NCT01233752 — intervention group
Intervention type: DRUG
Intervention: morphine chlorhydrate
Description: The drug will be administrated by a bolus 45 minutes before the end of the surgery, with the following modalities: bolus with morphine chlorhydrate 0.15 mg/kg ± 20%. Also acetaminophene 1g and ketoprofen 160 mg (ketorolac 30mg) will be administrated during the operation.~At the exit of the operative compartment patients will have an electronic pump (PCA) for 48h with morphine chlorhydrate to be used in boluses by 1 mg with a lock out of 5 mins, max dose 20 mg in 4 hours.~Moreover, ketoprofen will be prescribed 160 mg x 2 per day (ketorolac 30mg x 2) (in case of allergy acetaminophene 1g x 3 daily).~Postoperative analgesic treatment is lasting 48h for each patient (between starting of the PCA infusion (T0) and the following 48h).
Study NCT02066077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate
Study NCT02066077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etomidate
Study NCT02066077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Study NCT02066077 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilateral temporal MECT
Study NCT02066077 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral temporal MECT
Study NCT02066077 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The right temporal MECT
Study NCT02066077 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilateral frontal MECT
Study NCT02373007 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Scopinaro Surgery
Description: Classic Scopinaro Technique is a bariactric surgery that proposes the stomach will be divide in two parts: a proximal part and a distal part for performing horizontal gastrectomy. Differently what will happen in the Modified Scopinaro Surgery that will divide the stomach in two parts: a proximal part and a distal part for performing gastroplasty.
Study NCT03691506 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classic CIMT group
Description: Constraint Induced Movement Therapy (CIMT) is a new treatment technique that claims to improve the arm motor ability and the functional use of a paretic arm - hand. CIMT forces the use of the affected side by restraining the unaffected side. Child with hemiplegic cerebral palsy can learn to improve the motor ability of the more affected parts of their bodies and thus cease to rely exclusively or primarily on the less affected parts.
Study NCT03691506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified CIMT group
Description: Modified CIMT protocol that was based on suggestions made by Dromerick, Edwards, and Hahn (2000) . Modifications were reductions in the duration of mitt wear and massed practice compared with the traditional protocol
Study NCT02419794 — intervention group
Intervention type: PROCEDURE
Intervention: endovascular treatment
Description: endovascular treatment for acute ischemic stroke patients with large vessel occlusion
Study NCT01410240 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Conventional hemostatic techniques, such as cautery and manual compression, will be used.
Study NCT01410240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOSEAL Hemostatic Matrix + Standard of care
Description: FLOSEAL will be applied topically to areas of the knee where bleeding is observed (e.g. cut bone surfaces, subcutaneous tissue, posterior joint capsule, synovial tissue, medial and lateral gutters, branches of the genicular vessels, and suprapatellar pouch) and will occur intraoperatively. Sufficient amounts of FLOSEAL will be applied quickly using the provided applicators, followed by immediate approximation with a damp gauze, lap pad or sponge for approximately 2 minutes.~+ Standard of care: conventional hemostatic techniques, such as cautery and manual compression, will be used
Study NCT03235362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR1706
Description: Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days in each period.
Study NCT04348500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clazakizumab
Description: IV Infusion
Study NCT04348500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clazakizumab
Description: IV Infusion
Study NCT00593606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Strength: 2,4,6,and 8mg/24h, form: transdermal application, once daily application
Study NCT01309750 — intervention group
Intervention type: RADIATION
Intervention: Small Bowel Transit Study
Description: Patients that are enrolled and consented in the study will be given 300ml of water containing 5 millicurie (mCi) of technetium-99m (Tc-99m) diethylenetriamine pentaacetate (DTPA). This nuclear tracer/water mix will either be drank orally or placed down a nasogastric tube to begin the study. The patient will have to have nothing else to eat or drink for the duration of the study. The patients will have a nuclear scan performed at 2, 4, and 6 hours after ingestion of the nuclear tracer.
Study NCT03872141 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative measures of reduction in Chemotherapy Induced Neuropathy (CIPN) and Cognitive Impairment (CICI) in patients with stage I-III breast cancer
Description: Quantitative measures that include additional aspects of peripheral neuropathy, such as pain, thermal allodynia, numbness and tingling are needed. We propose to evaluate several pharmacodynamics biomarkers in patients before and during chemotherapy: changes in nerve conduction velocity and amplitude, quantitative sensory testing (QST), computer based cognitive assessment, and rate of drop-out from treatment. The tests from this list that best correlate with decreased CIPN would be added to EORTC QLQ-CIPN20 scores and will provide an early indication of CIPN and/or CICI.
Study NCT03576209 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: healthy lifestyle program
Description: Participants (intervention group) are following a 12 week health promotion program. They will count daily steps by pedometers and participate in weekly organised walks (within socio-cultural organisation)
Study NCT03235362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR1705+YHR1706
Description: Subjects will receive multiple oral doses of YHR1705 + YHR1706 QD for 5 consecutive days in each period.
Study NCT01003262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emergency Department Observation Protocol
Description: The EDOSP will consist of cardiac enzyme testing, 12-24 hours of cardiac monitoring, and echocardiogram testing by explicit criteria
Study NCT01003262 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unstructured, inpatient evaluation
Description: This is unstructured management by an inpatient medical team.
Study NCT00480675 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trochanteric bursa injection done under fluoroscopy with depomedrol and bupivacaine
Description: Depomedrol 60 mg + bupivacaine 2.5 ml
Study NCT00480675 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trochanteric bursa injection with depomedrol and bupivacaine
Description: Trochanteric bursa injection done with sham x-ray and 60 mg of depomedroal and 2.5 ml bupivacaine using landmarks for guidance.
Study NCT03324971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medications review
Description: Medications review. Elimination of all unnecessary prescription to cut down the number of medications to the least possible number.~This is in line with the best practice guidelines.
Study NCT04011293 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNCT19
Description: 0.5 to 4 x 10\^6 autologous CNCT19 transduced cells per kg body weight, with a maximum dose of 4 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion.
Study NCT00080990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV
Study NCT00080990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT00080990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT03495115 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: A MRI uses a strong magnet to produce detailed pictures of the inside of your body.
Study NCT03495115 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RSI
Description: RSI is a technique that aims to improve the pictures produced during a MRI exam.
Study NCT04480996 — intervention group
Intervention type: DRUG
Intervention: Drugs Responsible for Cognitive Side Effects
Description: identification of road traffic accidents associated with drugs responsible for psychomotor side effects
Study NCT00998205 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dobutamine stress echo (DSE)
Description: Dobutamine intravenous infusion would be undertaken starting at 10 micro-grams/kg per minute in three minute intervals increased to 20, 30, 40 or 50 micro-grams/kg per minute or to a peak heart rate response of at least 85% age predicted maximum heart rate.
Study NCT00998205 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atropine bolus
Description: If at the end of the Dobutamine protocol, there is inadequate heart rate response, intravenous atropine boluses of 0.5 milligrams (maximum 1.0 mg) would be used as needed to achieve a heart rate of at least 85% of age predicted maximum heart rate.
Study NCT00080990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT03118245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AuraGain
Description: After anesthetic induction, AuraGain is inserted in children
Study NCT03118245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-gel
Description: After anesthetic induction, I-gel is inserted in children
Study NCT02716363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotational Atherectomy by Rotablator
Study NCT04470869 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phone call
Description: The relatives of both groups will be contacted by phone one month after the discharge of the ICU of the death, three month after, six month after and twelve month after. During these interviews the PTSD symptoms, the anxiety and depression symptoms, the complicated grief symptoms (in case of death) and the satisfaction about the ICU stay will be collected.
Study NCT04470869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone call
Description: The relatives of both groups will be contacted by phone one month after the discharge of the ICU of the death, three month after, six month after and twelve month after. During these interviews the PTSD symptoms, the anxiety and depression symptoms, the complicated grief symptoms (in case of death) and the satisfaction about the ICU stay will be collected.
Study NCT02485899 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMN 190
Description: 300 mg Intracerebroventricular (ICV) infusion administered every other week for up to 240 weeks
Study NCT02485899 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracerebroventricular (ICV) access device
Description: Surgical implantation of an MRI compatible ICV access device in the lateral ventricle of the right hemisphere is required for administration of study drug.
Study NCT00672282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: 150mg p.o. daily
Study NCT00672282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03497715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen lysine
Description: Test 1
Study NCT03497715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen Sodium
Description: Test 2
Study NCT03497715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Test 3
Study NCT03497715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen (Nurofen)
Description: Reference 1
Study NCT01147211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK2206
Description: MK-2206 will be administered orally in a starting dose level of 135 mg on a schedule of Qwk in repeating 3-week treatment cycles in combination with gefitinib in continuous 21-day cycles for the duration of the study
Study NCT01185054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ½ strength apple juice
Description: For each episode of diarrhea 10 ml/kg of fluid will be given and for each episode of vomiting 2 ml/kg will be given. If the child does not like the solution another fluid can be used.
Study NCT01185054 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pediatric Electrolyte
Description: For each episode of diarrhea 10 ml/kg of fluid will be given and for each episode of vomiting 2 ml/kg will be given. If the child does not like the solution another electrolyte maintenance fluid can be used. Fluids containing non-physiological concentrations of glucose and electrolytes (carbonated drinks, sweetened fruit juices, water) will be discouraged.